the future

Maryam Rahman; W. Gregory Sawyer; Scott Lindhorst; Loic P. Deleyrolle; Jeffrey K. Harrison; Aida Karachi; Farhad Dastmalchi; Joseph Flores-Toro; Duane A. Mitchell; Michael Lim; Mark R. Gilbert; David A. Reardon

doi:10.1093/neuonc/noaa116

the future

Maryam Rahman, W. Gregory Sawyer, Scott Lindhorst, Loic P. Deleyrolle, Jeffrey K. Harrison, Aida Karachi, Farhad Dastmalchi, Joseph Flores-Toro, Duane A. Mitchell, Michael Lim, Mark R. Gilbert, David A. Reardon

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In oncology, “immunotherapy” is a broad term encompassing multiple means of utilizing the patient’s immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.

Original language	English (US)
Pages (from-to)	1249-1261
Number of pages	13
Journal	Neuro-oncology
Volume	22
Issue number	9
DOIs	https://doi.org/10.1093/neuonc/noaa116
State	Published - Sep 1 2020

Keywords

Brain cancer
Failure analysis
Glioblastoma
Glioma
Immunology
Immunotherapy

ASJC Scopus subject areas

Oncology
Clinical Neurology
Cancer Research

Access to Document

10.1093/neuonc/noaa116

Cite this

@article{8e2bf96fed474ab1a08081a973762f22,

title = "the future",

abstract = "In oncology, “immunotherapy” is a broad term encompassing multiple means of utilizing the patient{\textquoteright}s immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.",

keywords = "Brain cancer, Failure analysis, Glioblastoma, Glioma, Immunology, Immunotherapy",

author = "Maryam Rahman and Sawyer, {W. Gregory} and Scott Lindhorst and Deleyrolle, {Loic P.} and Harrison, {Jeffrey K.} and Aida Karachi and Farhad Dastmalchi and Joseph Flores-Toro and Mitchell, {Duane A.} and Michael Lim and Gilbert, {Mark R.} and Reardon, {David A.}",

year = "2020",

month = sep,

day = "1",

doi = "10.1093/neuonc/noaa116",

language = "English (US)",

volume = "22",

pages = "1249--1261",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - the future

AU - Rahman, Maryam

AU - Sawyer, W. Gregory

AU - Lindhorst, Scott

AU - Deleyrolle, Loic P.

AU - Harrison, Jeffrey K.

AU - Karachi, Aida

AU - Dastmalchi, Farhad

AU - Flores-Toro, Joseph

AU - Mitchell, Duane A.

AU - Lim, Michael

AU - Gilbert, Mark R.

AU - Reardon, David A.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - In oncology, “immunotherapy” is a broad term encompassing multiple means of utilizing the patient’s immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.

AB - In oncology, “immunotherapy” is a broad term encompassing multiple means of utilizing the patient’s immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.

KW - Brain cancer

KW - Failure analysis

KW - Glioblastoma

KW - Glioma

KW - Immunology

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85092332282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092332282&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noaa116

DO - 10.1093/neuonc/noaa116

M3 - Article

C2 - 32391559

AN - SCOPUS:85092332282

SN - 1522-8517

VL - 22

SP - 1249

EP - 1261

JO - Neuro-oncology

JF - Neuro-oncology

IS - 9

ER -

the future

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this